ArriVent BioPharma, Inc. Common Stock (AVBP) Financial Analysis & Valuation | Quarter Chart
ArriVent BioPharma, Inc. Common Stock (AVBP)
AVBPPrice: $19.82
Fair Value: 🔒
🔒score
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therap... more
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the ... more
Description
Shares
| Market Cap | $818.16M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Zhengbin Yao |
| IPO Date | 2024-01-26 | CAGR | — |
| Employees | 52 | Website | www.arrivent.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
AVBP chart loading...
Fundamentals
Technicals
| Enterprise Value | $649.42M | P/E Ratio | -4.51 |
| Forward P/E | -8.44 | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 2.78 |
| P/CF Ratio | -5.48 | P/FCF Ratio | -6.46 |
| EPS | $-4 | EPS Growth 1Y | 75.93% |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.55% | ROA | -0.51% |
| ROCE | -0.59% | Current Ratio | 12.74 |
| Quick Ratio | 12.74 | Cash Ratio | 5.74 |
| Debt/Equity | 0 | Interest Coverage | — |
| Altman Z Score | 20.72 | Piotroski Score | 1 |
View ArriVent BioPharma, Inc. Common Stock financial charts →